Health Professional Radio - Podcast

Returning guest, Dr. David Spetzler, President and Chief Scientific Officer at Caris Life Sciences® discusses the partnership with Elevation Oncology to identify patients for participation in Elevation Oncology’s CRESTONE trial, a Phase 2 trial of seribantumab in adult patients with recurrent, locally advanced, or metastatic solid tumors that harbor the NRG1 gene fusion. He talks about the significance of this partnership and discusses how Caris’ AI-based platform can allow companies to maximize their clinical trials and identify treatments for patients using precision medicine.